Does This Star ‘GLO’? Taking Aim at Second-Line Diffuse Large B-Cell Lymphoma With Glofitamab Plus Gemcitabine and Oxaliplatin

March 31, 2025
Speakers: Tycel Phillips, MD, Jeremy Abramson, MD

In this episode, Contributing Editor Tycel Phillips, MD, an associate professor of medicine and a hematologist-oncologist at City of Hope Medical Center in Duarte, California, talks with Jeremy Abramson, MD, director of the Jon and Jo Ann Hagler Center for Lymphoma at Massachusetts General Hospital and an associate professor of medicine at Harvard Medical School. They talk about the use of Glofit-GemOx in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Support for this episode provided by Autolus.

The Rise of the HLA-Mismatched Unrelated Donor Transplant in the U.S.

February 27, 2025
Speakers: Lori Muffly, MD, MS, and Steven Devine, MD

In this episode, Contributing Editor Lori Muffly, MD, MS, an associate professor of medicine at Stanford University where she focuses on cellular therapy for adults with acute leukemia, talks with Steven Devine, MD, the chief medical officer at the National Marrow Donor Program. They talk about the rise of HLA-mismatched unrelated donor transplants in the U.S.

The End of Transplant for Mantle Cell Lymphoma

January 31, 2025
Speakers: Brian Hill, MD, PhD, and Tim Fenske, MD

In this episode, Contributing Editor Brian Hill, MD, PhD, director of the lymphoid malignancies program at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, talks with Tim Fenske, MD, who at the time of this recording was joining the transplant and cell therapy group at Sara Cannon Methodist Healthcare in San Antonio, Texas. Dr. Fenske previously led the lymphoma program at the Medical College of Wisconsin. They talk about a new study that found a lack of benefit in autologous stem cell transplantation for patients with mantle cell lymphoma.